What Is Jeff Brown’s Stunning Confession?

Brownstone Research has been promoting a pitch by Jeff Brown about a “Stunning Confession” he made to his readers.

It involves a technology that was a lifesaver for him that he says could end up being “the #1 investment of 2021.”

In this article, I will be unpacking and highlighting the main talking points of the presentation as well as reveal the companies he wants you to consider adding to your portfolio.

No.1 recommendation….

Want to see my no.1 recommendation for making money online?

This made us 6-figures in the last 3 months:

Go here to see my no.1 recommendation for making money online

What is Jeff Brown’s Stunning Confession? (The Pitch)

Jeff Brown’s Stunning Confession is a presentation that was hosted by Chris Hurt in which Jeff shares a heartfelt story about how he learned that he has Prostate Cancer while researching a biotech stock.

Jeff Brown's Stunning Confession 3

I hope he recovers fully and gets to spend more time with his family.

Now, what does his confession have to do with investing and new trends (because that’s the endgame here)?

It is all about investing in a new trend indirectly.

One example he gives of this is how he invested in digital currencies. In the cryptocurrency craze, he didn’t pick a digital currency but chose to go with the underlying tech that powers it and recommended AMD, which makes the microprocessors used to mine cryptos.

That is the same approach he wants to take with the biotech sector. He says,

“You see, Chris, I help subscribers learn how to make money by focusing on industry-altering trends right around the corner.

And I am doing it again now.

Look, I know the biotech industry is hot.

But I’m not just picking between one drug or the other here.

You can make money with individual biotech stocks for sure…

But I believe you can essentially profit from the whole sector… if you know where to look.

I believe this is possibly the most important investment story of the next decade…”

So, what underlying trend has he decided to focus on?

He is referring to precision medicine,

“Chris, I’m talking about precision medicine.

It’s a game-changer for the future of the medical industry.

Millions of lives will be saved… as well as billions of dollars…

Patients will benefit from the more specific treatments that they will receive in the future.”

This is not Jeff’s first time to talk us into investing in Biotech companies. We’ve seen him talk about them in other presentations I have reviewed here, including one titled The Great Reset and another called The Cure.

Circling back to precision medicine, here is how he describes it, quoting the Precision Medicine Initiative,

“Now, according to the Precision Medicine Initiative, precision medicine is “an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person.”

And here’s the key…

Instead of a one-size-fits-all approach, we’re moving to a place where individual patients are the focus of medicine.”

Now we get to the investments.

Recommended: Go here to see my no.1 recommendation for making money

How does Jeff want us to invest in precision medicine?

The angle Jeff chooses to approach this with is that precision medicine is a confluence of multiple disruptive technologies. He argues that if you can identify the underlying technologies behind precision medicine and invest in the companies involved with those technologies, you will benefit from the precision medicine trend.

In this case, he says that artificial intelligence and machine learning are crucial to precision medicine.

What are his stock picks?

The first one does genetic sequencing,

“This company is working hard to get the price of a full genetic sequencing under $100.

It currently controls roughly 75% of the global market share.

And it’s one of the most important players in the world of genetic sequencing.

Numerous companies and governments around the world are collecting data on the full genomes of their population…

And many are using this company’s equipment to sequence patient DNA.

It’s so well-respected worldwide that the Food and Drug Administration (FDA) issued them what’s called an emergency use authorization (EUA) in the midst of the pandemic.

This was so its technology could be utilized in combating Covid-19.”

He has written a report about it called The #1 Precision Medicine Stock of the 2020s. In it, he reveals the name and ticker symbol for the company as well as why he thinks it is perfectly positioned to dominate genetic sequencing.

However, you don’t have to wait for the report because I pieced the clues together and I think he is likely referring to Illumina Inc (ILMN), which received a EUA from the FDA in June last year (2020). Illumina develops, makes, and sells integrated systems for the analysis of genetic variation and biological function. Jeff must also really like it because he recommended it in another presentation titled Tech Melt (The Second Wave).

There is a second pick in the special report,

“In this special briefing, I will also include a bonus precision medicine pick…

According to its most recent earnings report, this company has around 30 product candidates in clinical development… right now.

Total revenues for the company increased by 30% in a year, to nearly $8.5 billion, in 2020.

Its top selling drug earned nearly $5 billion in the United States alone.

Several others are also performing well, while other top drug candidates are already working their way through the pipeline.

And much like the first company in this report, my second recommendation is fighting COVID-19.

It too has been issued an emergency use authorization by the Food and Drug Administration…

Its antibody cocktail was given to former President Trump, who praised its effects.

And they were recently awarded a $2.6 billion contract by the U.S. Army.”

The company that fits this description is Regeneron Pharmaceuticals Inc. (REGN). It made the COVID-19 emergency therapy that was taken by President Trump when he contracted the virus in October 2020. It got FDA approval for the experimental therapy in November.

And there’s a third company he has picked that deals with Cystic Fibrosis Therapeutics,

“It’s had four medicines approved for cystic fibrosis since 2012 alone.

Three of these medications have helped up to 90% of those who have this disease.

But this company is determined to reach 100%… All 100,000, and anyone else who follows.

It made a $105 million commitment to partner with a gene-editing giant way back in 2015 with the goal of eventually curing many diseases.”

The company that fits this description is Vertex Pharmaceuticals (VRTX). It is a pharmaceutical company based in Boston that has been developing therapies to combat Cystic Fibrosis. Since 2012, it has had four therapies approved with the latest being Trikafta in 2019. Trikafta improved on the previous therapy (called Kalydeco) and can now help 90% of patients.

Jeff wrote a report about it called The Company Behind Cystic Fibrosis’ Demise.

Recommended: Go here to see my no.1 recommendation for making money

The fourth company he teases is in the technology sector and unlike the others, it is not working on some cure for a disease. Instead, it is developing the infrastructure used by the other pick and shovel companies in precision medicine. Jeff says,

“This company is not working on drug discovery…

It’s not fighting a specific disease…

But it does provide a crucial technology…

No matter which precision medicine companies rise or fall… I believe they’ll all benefit from this company’s special piece of technology.

And this is why…

It could impact several of those disruptive technologies that will, in turn, impact precision medicine.

This company began investing in 5G products as far back as 2014, years before the rollout.

In fact, I believe you can think of it as a 5G company above all else right now.

I do.

But it is also already developing products for artificial intelligence, machine learning, and even quantum computing.

24 of the top 25 tech companies in the world employ this company’s proprietary technology.”

He says that things like AI and quantum computing need this company’s unique tech to perform optimally. He continues,

“Chris, this company is best known right now for producing equipment to gather test results for 5G devices.

These tests show how well a 5G wireless network is performing.

That’s why I view them as a company more aligned with the 5G wireless boom right now.

I believe this company is already the best test and measurement equipment manufacturer…”

He then says that 75% of all 5G equipment in the field has been developed with its testing and measurement tools and software. It could also have an impact on quantum computing by enabling faster testing and control.

I am not sure about this one but he could be referring to Teradyne (TER). It is an automatic test equipment designer and manufacturer that has some high-profile customers. Among its clients are Samsung, Intel, Analog Devices, Texas Instruments, IBM, and Qualcomm. In terms of 5G, it provides RF semiconductor test solutions to network providers.

Jeff wrote a report about it called My #1 Stock “Behind” Quantum Computing’s Rise.

There is also another company he wants you to consider investing in that develops a therapy for hemophiliacs. He says,

“Now it has its eyes squarely set on a genetic disorder affecting more than 157,000 people worldwide.

I’m talking about hemophilia A.”


“The company recently announced that the therapy it has developed to combat this genetic disorder had a positive impact.

A study featuring over 100 patients showed the therapy reduced average annual treatments from 136 down to just 2.

That is a drop of 99%.

This company has the lead therapy candidate for hemophilia A.”

Although I am not certain about this one too, I think he may be referring to BioMarin Pharmaceutical (BMRN) because it is the most advanced in the development of a hemophilia A therapy candidate. It submitted a Biologics License Application (BLA) for its gene therapy based on phase I/II trials and interim phase III results but was declined approval in 2020. In January (2021), it showed positive results for its phase III trial and hopes to get its approval effort back on track. Other biotech companies working on hemophilia A therapies are in phase I/II trials.

He wrote a report about it called My #1 Gene Therapy Stock.

Recommended: Go here to see my no.1 recommendation for making money

Who is Jeff Brown?

Jeff Brown is an angel investor and a former tech executive. He regards himself as one of the leading angel investors in Silicon Valley.

Speaking of his stint as a tech executive – which spanned 30 years – Jeff has worked for some of the most recognizable technology companies in the world. For instance, he was the head of Global Strategy for a division of Qualcomm. He also worked for NXP Semiconductors and says that he helped them revive their floundering Japanese branch by focusing on advanced semiconductors.

He is also well educated, with degrees from London Business School and Purdue University. In the latter, he was in the Astronautical and Aeronautical Engineering program.

He publishes his work via Brownstone Research – which he founded. His most popular newsletters are The Near Future Report, The Bleeding Edge, and Exponential Tech Investor.

Recommended: Go here to see my no.1 recommendation for making money

What is The Near Future Report? (The Newsletter)

To get all the aforementioned special reports for free, you have to sign up for The Near Future Report. It is one of the premium newsletters that Jeff Brown publishes via Brownstone Research.

When you sign up for it, you receive Jeff’s insights on how to profit from “the exploding tech market.” He says that you get to leverage his experience as a tech executive and angel investor to find out about rapid advances in technology before the rest of the world does.

He says that the companies he recommends are not the ones that will make money many years from now, but those that will earn you returns in the short term.

When you become a member, on top of the reports, you get:

  • 12 monthly issues of the newsletter.
  • Past and future special reports.
  • Access to the members’ portfolio 24/7

How much do you pay to join The Near Future Report?

An annual subscription costs $49 if you join through the link at the bottom of the presentation. The membership renews at $129 per year after the first year.

Does The Near Future Report have a Refund Policy?

They give refunds if you cancel your membership within 60 days.

Recommended: Go here to see my no.1 recommendation for making money

Closing Remarks on Jeff Brown’s Stunning Confession

Jeff Brown’s Stunning Confession about him having cancer morphed into a conversation about the best pick and shovel companies that will drive the multi-billion dollar precision medicine trend. This is a common tactic used by newsletter gurus to get people to subscribe to their newsletters; they tease some promising stock picks with convincing backgrounds and suggest that you can get more of that if you join their newsletter. This is no different.

To recap the stocks he teased:

  • Illumina Inc (ILMN)
  • Regeneron Pharmaceuticals Inc. (REGN)
  • Vertex Pharmaceuticals (VRTX)
  • Teradyne (TER)
  • BioMarin Pharmaceutical (BMRN)

Finally, do not sign up for a service just because you were impressed by a presentation and found the story moving. There is always more to it than that and the best way to find out what a newsletter is all about is to do more research.

Before you go…

Want to see my no.1 recommendation for making money online?

This made us 6-figures in the last 3 months:

Go here to see my no.1 recommendation for making money online